Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$34.6 million","upfrontCash":"Undisclosed","newsHeadline":"MBX Debuts with $35M to Bankroll Rare Endocrine Pipeline","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Wellington Management","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"IND Enabling"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBX Biosciences Doses First Participant in Phase 1\/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by MBX Biosciences

    Menu

    MBX Biosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              MBX Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

              Details:

              MBX 1416 is an investigational long-acting GLP-1 receptor antagonist in development as a potential treatment for Post-Bariatric Hypoglycemia. It was designed using the company’s novel, proprietary PEP platform to prevent the occurrence of severe hypoglycemia.

              Lead Product(s): MBX 1416

              Therapeutic Area: Endocrinology Product Name: MBX 1416

              Highest Development Status: Phase I/ Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MBX Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults

              Details:

              MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy for hypoparathyroidism. It was designed with the company’s novel, proprietary Precision Endocrine Peptide™ (PEP™) platform technology.

              Lead Product(s): MBX 2109

              Therapeutic Area: Endocrinology Product Name: MBX 2109

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MBX Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

              Details:

              MBX 1416 is an investigational long-acting GLP-1 receptor antagonist in development as a potential treatment for Post-Bariatric Hypoglycemia. It was designed using the company’s novel, proprietary PEP platform to prevent the occurrence of severe hypoglycemia.

              Lead Product(s): MBX 1416

              Therapeutic Area: Endocrinology Product Name: MBX 1416

              Highest Development Status: IND Enabling Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MBX Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs

              Details:

              Proceeds of the financing will support clinical advancement of its lead product candidate, MBX 2109, an investigational long-acting parathyroid hormone peptide prodrug, which is in development for the treatment of hypoparathyroidism and currently in a Phase 1 clinical trial.

              Lead Product(s): MBX 2109

              Therapeutic Area: Endocrinology Product Name: MBX 2109

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Wellington Management

              Deal Size: $115.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing November 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MBX Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109

              Details:

              MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy. MBX 2109 was observed to be safe and well tolerated, as compared to placebo.

              Lead Product(s): MBX 2109

              Therapeutic Area: Endocrinology Product Name: MBX 2109

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MBX Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism

              Details:

              MBX 2109, an investigational PTH prodrug in development designed with novel, proprietary prodrug to provide sustained PTH activity with dosing regimen to simplify an individual’s disease management, while relieving both symptoms of disorder and long-term complications.

              Lead Product(s): MBX 2109

              Therapeutic Area: Endocrinology Product Name: MBX 2109

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MBX Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MBX Debuts with $35M to Bankroll Rare Endocrine Pipeline

              Details:

              Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets.

              Lead Product(s): Undisclosed

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: Frazier Healthcare Partners

              Deal Size: $34.6 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing July 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY